Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies

Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies

Alpha-synuclein is a 15 kDa protein associated with neurodegenerative diseases such as Parkinson disease and multiple-system atrophy where pathological forms of alpha-synuclein aggregate and become neurotoxic. Here we describe the nonclinical program to support a first-in-human (FIH) single ascendin...

Full description

Bibliographic Details
Main Authors: Lone Fjord-Larsen, Annemette Thougaard, Karen Malene Wegener, Joan Christiansen, Frank Larsen, Lise Maj Schrøder-Hansen, Marianne Kaarde, Dorte Kornerup Ditlevsen
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:mAbs
Subjects:
Alpha-synuclein
cerebrospinal fluid
monoclonal antibody
nonclinical safety
pharmacokinetics
target engagement
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2021.1994690

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2021.1994690

Similar Items